Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

News, archive: November 2020

11/30/2020 Pharmaceutical Drug Production in Russia (October 2020)

Between January and October 2020, Russia manufactured RUB 399.1 bln worth of pharmaceutical drugs (manufacturer’s prices, VAT included), which is in monetary terms (rubles) 17% higher than in 2019. These dynamics are significantly lower, compared to the dynamics of the period between Q1 and Q3. The dynamics in physical terms are even less promising: +12.4% in units and +15.2% in minimum dosage units (MDU). The production volume in physical terms amounts to 4 bln units, or 68.4 bln MDUs.

11/26/2020 Ranking of Russian Pharmacy Chains (Q1 – Q3 2020)

It seems that the moment of truth will come to the Russian pharmaceutical retail market next year. After several years of relatively stable development and a number of waves of rush demand in 2020, 2021 may become a period of a most severe crisis, making all the current problems associated with the launch of the labeling system seem like mere trifles.

11/23/2020 Ranking of Russian Pharmaceutical Distributors (Q1 – Q3 2020)

The incidence of COVID-19 has been going up since September, with November bringing records one after another, both in large cities and in Russia as a whole. Naturally, the demand for certain “corona-specific” drugs has also been increasing. With that more or less predicted, the market participants at all stages of commodity distribution, including wholesale, were preparing for an increase in morbidity associated with the end of the vacation season and the start of the school year when the labeling system altered the situation.

11/19/2020 Database Update: Audit of Veterinary Drug Retail Sales in Russia (October 2020)

Between January and October 2020, the sales of veterinary drugs in the retail market amounted to RUB 17.6 bln (retail prices, VAT included), which is in monetary terms (rubles) 0.1% lower than in 2019. The volume in physical terms is 159.3 bln minimum dosage units (MDU), which is 0.9% lower than in 2019.

11/10/2020 Pharmaceutical Drug Import for Clinical Trials to Russia (September and Q1 – Q3 2020)

Between January and September 2020, Russia imported RUB 18.3 bln worth of pharmaceutical drugs for clinical trials (CT) (customs clearance and VAT included), which is in monetary terms (rubles) a bit more than 40% higher than in 2019. The dynamics in physical terms (units) are somewhat lower, +17%, with the import volume of 672,000 units.

11/3/2020 Pharmaceutical Drug Production in Russia (September and Q1 – Q3 2020)

Between January and September 2020, Russian manufacturers produced RUB 356.2 bln worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), which is in monetary terms (rubles) 20.8% higher than in 2019. The dynamics in physical terms (units) are +10.5%, with the manufacture volume of 3.5 bln units. If calculated in minimum dosage units (MDU), the dynamics are +14.2%.